[Editor Note: This section is applicable to all applications with a filing date, or, for national phase applications, an international filing date, on or after July 1, 2022, having disclosure of one or more nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). Formatting representations of XML (eXtensible Markup Language) elements in this section appear different than shown in Standard ST.26, which may be accessed at: www.wipo.int /export/sites/www/ standards/en/pdf/03-26-01.pdf.]

37 C.F.R. 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.

1. *****

2. (g) "Modified amino acid" includes any amino acid as described in paragraph 3(e) of WIPO Standard ST.26.

3. *****

WIPO Standard ST.26, paragraph 3(e), defines "modified amino acid" to mean any amino acid as described in the definition of "amino acid", other than L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-pyrrolysine, L-serine, L-selenocysteine, L-threonine, L-tryptophan, L-tyrosine, or L-valine. See MPEP § 2412.03(b).

Modified amino acids, including D-amino acids, should be represented in the sequence as the corresponding unmodified amino acids whenever possible. Any modified amino acid in a sequence that cannot otherwise be represented by a symbol set forth in Table 3 must be represented by "X", i.e., an "other" amino acid.

A modified amino acid must be further described in a feature table. See MPEP § 2413.01(g), subsection I, for discussion of a "feature table". Where applicable, the feature keys "CARBOHYD" or "LIPID" should be used together with the qualifier "note". The feature key "MOD_RES" should be used for other post-translationally modified amino acids together with the qualifier "note". The feature key "SITE" together with the qualifier "note" should be used when the modified amino acid is not a post-translationally modified amino acid. See MPEP § 2413.01(g), subsections II and III, for discussion of a "feature key". The value for the qualifier "note" must either be an abbreviation set forth in Table 4 below or the complete, unabbreviated name of the modified amino acid. The abbreviations set forth in Table 4 or the complete, unabbreviated names must not be used in the sequence itself.

Reproduced from WIPO Standard ST.26, Annex I, Section 4.